Quantitative ferumoxytol-enhanced MRI in pregnancy: A feasibility study in the nonhuman primate

• Published in: Magnetic resonance imaging 2020-01, Vol.65, p.100-108
• Main Authors: Zhu, Ante, Reeder, Scott B., Johnson, Kevin M., Nguyen, Sydney M., Fain, Sean B., Bird, Ian M., Golos, Thaddeus G., Wieben, Oliver, Shah, Dinesh M., Hernando, Diego
• Format: Article
• Language: English
• Subjects: Animals; Contrast Media - pharmacology; Feasibility Studies; Female; Ferrosoferric Oxide - pharmacology; Ferumoxytol; Inflammation; Interleukin-1beta - metabolism; Iron - analysis; Macaca mulatta; Magnetic Resonance Imaging; Magnetic susceptibility; Placenta; Placenta - drug effects; Pregnancy; Pregnancy, Animal; Prospective Studies; Quantitative
• ISSN: 0730-725X; 1873-5894
• DOI: 10.1016/j.mri.2019.10.006

To assess the feasibility of ferumoxytol-enhanced MRI in pregnancy with a nonhuman primate model. In this prospective study, eleven pregnant rhesus macaques at day 98 ± 5 of gestation were divided into three groups, untreated control (UC) (n = 3), saline control (SC) (n = 4) and interleukin 1 beta (IL-1β) treated (IT) (n = 4), which were administered with either saline or IL-1β into the amniotic fluid. All animals were imaged at multiple time points before and after ferumoxytol administration (4 mg/kg). Longitudinal R2* and susceptibility of tissues were obtained using region-of-interest analysis and the longitudinal changes were assessed using linear mixed models and Student's t-test. In fetuses, a slope of 0.3 s−1/day (P = 0.008), 0.00 ppm/day (P = 0.699) and − 0.2 s−1/day (P = 0.023) was observed in liver R2*, liver susceptibility, and lung R2*, respectively. In placentas, R2* and susceptibility increased immediately after ferumoxytol administration (P